Nov 1, 1986

Treatment of phenobarbitone poisoning with repeated oral administration of activated charcoal

The Quarterly Journal of Medicine
D A BoldyL F Prescott

Abstract

Six patients with moderate to severe phenobarbitone intoxication were treated with repeated oral doses (50 g) of activated charcoal following an initial dose of 50 to 100 g. All recovered more rapidly than would otherwise be expected with supportive care alone. The mean maximum rate of fall in plasma phenobarbitone concentrations corresponded to a half-life of only 6.2 +/- 2.5 h (normally three to five days); 62 to 93 per cent of the absorbed dose was eliminated within 24 h and the mean total body clearance of the drug during and for up to 12 h after administration of charcoal was 84 +/- 34 ml/min. Treatment with repeated oral doses of activated charcoal is simple and safe. It seems to be as effective as forced alkaline diuresis, haemodialysis and haemoperfusion for the removal of phenobarbitone following overdosage.

  • References
  • Citations

References

  • We're still populating references for this paper, please check back later.
  • References
  • Citations

Citations

  • This paper may not have been cited yet.

Mentioned in this Paper

Skin Lymphangiosarcoma
Diuresis
Poisoning Aspects
Poisoning
Charcoal
Phenobarbital
Activated Charcoal
Entire body as a whole
Luminal
Total Body Clearance Rate

About this Paper

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Bone Marrow Neoplasms

Bone Marrow Neoplasms are cancers that occur in the bone marrow. Discover the latest research on Bone Marrow Neoplasms here.

IGA Glomerulonephritis

IgA glomerulonephritis is a chronic form of glomerulonephritis characterized by deposits of predominantly Iimmunoglobin A in the mesangial area. Discover the latest research on IgA glomerulonephritis here.

Cryogenic Electron Microscopy

Cryogenic electron microscopy (Cryo-EM) allows the determination of biological macromolecules and their assemblies at a near-atomic resolution. Here is the latest research.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

LRRK2 & Immunity During Infection

Mutations in the LRRK2 gene are a risk-factor for developing Parkinson’s disease. However, LRRK2 has been shown to function as a central regulator of vesicular trafficking, infection, immunity, and inflammation. Here is the latest research on the role of this kinase on immunity during infection.

Antiphospholipid Syndrome

Antiphospholipid syndrome or antiphospholipid antibody syndrome (APS or APLS), is an autoimmune, hypercoagulable state caused by the presence of antibodies directed against phospholipids.

Meningococcal Myelitis

Meningococcal myelitis is characterized by inflammation and myelin damage to the meninges and spinal cord. Discover the latest research on meningococcal myelitis here.

Alzheimer's Disease: MS4A

Variants within membrane-spanning 4-domains subfamily A (MS4A) gene cluster have recently been implicated in Alzheimer's disease by recent genome-wide association studies. Here is the latest research.

Related Papers

British Journal of Clinical Pharmacology
L F PrescottR Heyworth
The New Zealand Medical Journal
K L LynnG S Gordon
Drug Safety : an International Journal of Medical Toxicology and Drug Experience
D J GrimesS M Pond
Medical Toxicology and Adverse Drug Experience
A Heath, K Knudsen
© 2020 Meta ULC. All rights reserved